UroGen Pharma Ltd. (URGN)
27.65
-4.08
(-12.86%)
USD |
NASDAQ |
Nov 20, 16:00
27.69
+0.04
(+0.14%)
After-Hours: 20:00
UroGen Pharma Total Liabilities (Quarterly) : 397.09M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 397.09M |
| June 30, 2026 | 384.99M |
| March 31, 2026 | 377.94M |
| December 31, 2025 | 305.93M |
| September 30, 2025 | 300.45M |
| June 30, 2025 | 302.09M |
| March 31, 2025 | 294.08M |
| December 31, 2024 | 294.51M |
| September 30, 2024 | 276.43M |
| June 30, 2024 | 251.54M |
| March 31, 2024 | 240.71M |
| December 31, 2023 | 243.52M |
| September 30, 2023 | 235.63M |
| June 30, 2023 | 233.80M |
| March 31, 2023 | 229.51M |
| December 31, 2022 | 224.98M |
| September 30, 2022 | 191.76M |
| June 30, 2022 | 187.05M |
| March 31, 2022 | 182.79M |
| Date | Value |
|---|---|
| December 31, 2021 | 111.33M |
| September 30, 2021 | 103.07M |
| June 30, 2021 | 97.50M |
| March 31, 2021 | 20.92M |
| December 31, 2020 | 25.65M |
| September 30, 2020 | 19.37M |
| June 30, 2020 | 18.42M |
| March 31, 2020 | 16.48M |
| December 31, 2019 | 22.09M |
| September 30, 2019 | 15.84M |
| June 30, 2019 | 13.79M |
| March 31, 2019 | 12.46M |
| December 31, 2018 | 13.46M |
| September 30, 2018 | 8.975M |
| June 30, 2018 | 7.952M |
| March 31, 2018 | 5.535M |
| December 31, 2017 | 7.035M |
| September 30, 2017 | 4.927M |
| June 30, 2017 | 4.966M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Xencor, Inc. | 210.07M |
| MeiraGTx Holdings Plc | 196.47M |
| Ironwood Pharmaceuticals, Inc. | 387.78M |
| Viking Therapeutics, Inc. | 388.57M |
| IDEAYA Biosciences, Inc. | 123.96M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 271.87M |
| Shareholders Equity (Quarterly) | -125.22M |
| Debt to Equity Ratio | -1.568 |
| Current Ratio | 3.403 |
| Net Debt Paydown Yield | -0.69% |